Get started

Financials · RDY

Dr. Reddy's Laboratories Ltd (RDY) financials

For fiscal 2026 (ended Mar 31, 2026), Dr. Reddy's Laboratories Ltd reported ₹335.93B of revenue and ₹42.85B of net income. Figures are in INR, the currency of its SEC filings.

Revenue, FY2026
₹335.93B
Revenue growth, YoY
+3.2%
Net income, FY2026
₹42.85B
Net income growth, YoY
-24.2%
Net margin
12.8%
Free cash flow, FY2026
₹33.43B
EPS, diluted, FY2026
₹51.42
EPS growth, YoY
-24.1%
Cash
₹15.37B
Total debt
₹12.20B
Annual revenue₹335.93B
FY2017FY2026
Annual net income₹42.85B
FY2017FY2026
Annual free cash flow₹33.43B
FY2017FY2026

RDY revenue and earnings growth

RDY revenueFY2026₹335.93B

FY YoY
+3.2%
5Y CAGR
+12.1%
10Y CAGR
+8.1%

RDY revenue was ₹335.93B for fiscal 2026 (ended Mar 31, 2026), up 3.2% from fiscal 2025. Compound annual growth was +12.1% over 5 years and +8.1% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2026 is the highest of the 11 fiscal years on file.

RDY net incomeFY2026₹42.85B

FY YoY
-24.2%
5Y CAGR
+20.0%
10Y CAGR
+7.9%

RDY net income was ₹42.85B for fiscal 2026 (ended Mar 31, 2026), down 24.2% from fiscal 2025. Compound annual growth was +20.0% over 5 years and +7.9% over 10 years. It rose in 6 of the last 10 fiscal years.

RDY EPSFY2026₹51.42

FY YoY
-24.1%
5Y CAGR
+19.9%
10Y CAGR
+8.2%

RDY diluted EPS was ₹51.42 for fiscal 2026 (ended Mar 31, 2026), down 24.1% from fiscal 2025. Compound annual growth was +19.9% over 5 years and +8.2% over 10 years.

RDY free cash flowFY2026₹33.43B

FY YoY
+76.6%
5Y CAGR
+5.2%
10Y CAGR
+1.4%

RDY free cash flow was ₹33.43B for fiscal 2026 (ended Mar 31, 2026), up 76.6% from fiscal 2025. Compound annual growth was +5.2% over 5 years and +1.4% over 10 years. It rose in 5 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item
FY2026
Mar 31, 2026
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
Revenue₹335.93B₹325.54B₹279.16B₹245.88B₹214.39B₹189.72B₹174.60B₹153.85B₹142.03B₹140.81B
Cost of revenue₹158.67B₹135.11B₹115.56B₹106.54B₹100.55B₹86.64B₹80.59B₹70.42B₹65.72B₹62.45B
Gross profit₹177.26B₹190.43B₹163.61B₹139.34B₹113.84B₹103.08B₹94.01B₹83.43B₹76.30B₹78.36B
Research and development₹24.06B₹27.38B₹22.87B₹19.38B₹17.48B₹16.54B₹15.41B₹15.61B₹18.27B₹19.55B
Selling, general and admin₹106.76B₹93.87B₹77.20B₹68.03B₹62.08B₹54.65B₹50.13B₹48.68B₹46.86B₹46.37B
Operating income₹50.55B₹71.84B₹67.73B₹57.14B₹29.48B₹24.28B₹15.99B₹20.89B₹11.92B₹13.50B
Interest expense₹3.74B₹2.83B₹1.71B₹1.43B₹958.00M₹970.00M₹983.00M₹889.00M₹788.00M₹634.00M
Pre-tax income₹54.82B₹76.78B₹71.87B₹60.37B₹32.30B₹26.41B₹18.03B₹22.44B₹14.34B₹14.65B
Income tax₹12.35B₹19.54B₹16.19B₹15.30B₹8.73B₹9.18B-₹1.47B₹3.65B₹4.54B₹2.61B
Net income₹42.85B₹56.54B₹55.68B₹45.07B₹23.57B₹17.24B₹19.50B₹18.80B₹9.81B₹12.04B
EPS, basic₹51.48₹67.88₹66.93₹54.28₹28.42₹20.79₹23.53₹22.66₹11.83₹14.45
EPS, diluted₹51.42₹67.78₹66.80₹54.17₹28.34₹20.73₹23.48₹22.62₹11.80₹14.42
Diluted shares833.3M834.2M833.5M831.9M831.7M831.6M830.4M831.0M830.9M835.0M

Balance sheet

Balance sheet
Line item
FY2026
Mar 31, 2026
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
Cash and equivalents₹15.37B₹14.65B₹7.11B₹5.78B₹14.85B₹14.83B₹2.05B₹2.23B₹2.64B₹3.87B
Receivables₹101.22B₹90.42B₹80.30B₹72.48B₹66.76B₹49.64B₹50.28B₹39.87B₹40.62B₹38.06B
Inventory₹76.53B₹71.08B₹63.55B₹48.67B₹50.88B₹45.41B₹35.07B₹33.58B₹29.09B₹28.53B
Current assets₹301.98B₹250.11B₹248.05B₹204.25B₹181.86B₹148.25B₹130.37B₹114.50B₹109.64B₹100.38B
Goodwill₹12.89B₹11.81B₹4.25B₹4.25B₹4.42B₹4.57B₹3.99B₹3.90B₹3.94B₹3.75B
Total assets₹579.35B₹492.99B₹387.52B₹321.85B₹292.83B₹265.49B₹232.24B₹225.43B₹225.60B₹219.82B
Current liabilities₹167.57B₹130.39B₹96.04B₹85.84B₹94.02B₹83.39B₹72.81B₹59.70B₹69.69B₹85.00B
Long-term debt₹12.20B₹7.86B₹5.99B₹1.28B₹5.75B₹6.30B₹1.30B₹22.00B₹25.09B₹5.45B
Total debt₹12.20B₹7.86B₹5.99B₹1.28B₹5.75B₹6.30B₹1.30B₹22.00B₹25.09B₹5.45B
Total liabilities₹198.89B₹155.82B₹106.97B₹90.86B₹102.30B₹92.43B₹77.25B₹85.23B₹99.14B₹95.78B
Shareholders' equity₹377.06B₹333.39B₹280.55B₹230.99B₹190.53B₹173.06B₹154.99B₹140.20B₹126.46B₹124.04B

Cash flow

Cash flow
Line item
FY2026
Mar 31, 2026
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
Operating cash flow₹56.76B₹46.43B₹45.43B₹58.88B₹28.11B₹35.70B₹29.84B₹28.70B₹18.03B₹21.51B
Capital expenditures₹23.33B₹27.50B₹16.40B₹11.32B₹14.66B₹9.74B₹4.85B₹6.96B₹9.29B₹12.28B
Free cash flow₹33.43B₹18.92B₹29.03B₹47.55B₹13.45B₹25.96B₹25.00B₹21.75B₹8.74B₹9.23B
Investing cash flow-₹65.51B-₹58.08B-₹40.28B-₹41.37B-₹26.39B-₹22.66B-₹4.92B-₹7.73B-₹14.88B-₹18.47B
Financing cash flow₹8.29B₹18.91B-₹3.76B-₹26.86B-₹2.42B-₹298.00M-₹25.16B-₹21.33B-₹4.44B-₹3.69B
Dividends paid₹6.66B₹6.66B₹6.65B₹4.98B₹4.15B₹4.15B₹3.92B₹4.00B₹3.99B₹3.39B
Share repurchases----₹0₹1.19B₹474.00M₹0₹0₹15.69B
Stock-based compensation₹326.00M₹424.00M₹407.00M₹397.00M₹592.00M₹584.00M₹521.00M₹389.00M₹454.00M₹350.00M
Depreciation and amortization₹20.61B₹17.06B₹14.84B₹12.64B₹11.82B₹12.80B₹12.47B₹12.19B₹11.71B₹11.28B

Key ratios

Key ratios
Line item
FY2026
Mar 31, 2026
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
Revenue growth, YoY3.2%16.6%13.5%14.7%13.0%8.7%13.5%8.3%0.9%-9.0%
Net income growth, YoY-24.2%1.5%23.6%91.2%36.7%-11.6%3.7%91.7%-18.5%-39.8%
EPS growth, YoY-24.1%1.5%23.3%91.2%36.7%-11.7%3.8%91.7%-18.2%-38.4%
Gross margin52.8%58.5%58.6%56.7%53.1%54.3%53.8%54.2%53.7%55.6%
Operating margin15.0%22.1%24.3%23.2%13.7%12.8%9.2%13.6%8.4%9.6%
Net margin12.8%17.4%19.9%18.3%11.0%9.1%11.2%12.2%6.9%8.5%
Free cash flow margin10.0%5.8%10.4%19.3%6.3%13.7%14.3%14.1%6.2%6.6%
Return on equity11.4%17.0%19.8%19.5%12.4%10.0%12.6%13.4%7.8%9.7%
Return on assets7.4%11.5%14.4%14.0%8.0%6.5%8.4%8.3%4.3%5.5%
Current ratio1.801.922.582.381.931.781.791.921.571.18
Debt to equity0.030.020.020.010.030.040.010.160.200.04

Source: XBRL data Dr. Reddy's Laboratories Ltd files with the SEC, latest filing dated May 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

Per-share figures and share counts are restated for stock splits the filings show: 5-for-1, first reported Jun 6, 2025.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

RDY peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RDY₹335.93B+3.2%₹42.85B12.8%$12.30B
TEVA$14.02B-16.4%$506.00M3.6%$51.92B
VTRS$14.73B+4.3%-$607.80M-4.1%$23.87B

RDY FAQ

9 questions
  • What is RDY revenue?
    Dr. Reddy's Laboratories Ltd (RDY) reported ₹335.93B of revenue for fiscal 2026 (ended Mar 31, 2026). That is up 3.2% from the year before.
  • Is RDY profitable?
    Yes. Dr. Reddy's Laboratories Ltd earned ₹42.85B in net income for fiscal 2026 (ended Mar 31, 2026), a net margin of 12.8%.
  • How much cash and debt does RDY have?
    Dr. Reddy's Laboratories Ltd reported ₹15.37B in cash and cash equivalents and ₹12.20B of debt on its most recent balance sheet in SEC filings.
  • How fast is RDY revenue growing?
    Dr. Reddy's Laboratories Ltd's revenue changed +3.2% in fiscal 2026, to ₹335.93B. Its compound annual growth rate was +12.1% over 5 years and +8.1% over 10 years.
  • What is RDY gross margin?
    Dr. Reddy's Laboratories Ltd's gross profit was ₹177.26B on ₹335.93B of revenue for fiscal 2026 (ended Mar 31, 2026), a gross margin of 52.8%.
  • What is RDY free cash flow?
    Dr. Reddy's Laboratories Ltd generated ₹33.43B of free cash flow for fiscal 2026 (ended Mar 31, 2026), which is operating cash flow of ₹56.76B less capital expenditures.
  • What is RDY earnings per share?
    Diluted earnings per share were ₹51.42 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.
  • When did RDY last report financial results?
    The latest statements here come from Dr. Reddy's Laboratories Ltd's 20-F filed on May 29, 2026, covering the period ended Mar 31, 2026.
  • Where does this RDY financial data come from?
    Quantisnow builds these statements from the structured XBRL data Dr. Reddy's Laboratories Ltd files with the SEC. It is provided for information only and is not investment advice.